💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)

By FDA, Pharmaceutical

💊Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)

SUMITOMO DAINIPPON PHARMA

http://www.ds-pharma.com/ir/news/pdf/ene20180307.pdf

More from tokioX :

  1. 💊Registration of Clinical Study Information and Disclosure of Clinical Study Results and Clinical Study Data
  2. 💊Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy
  3. 💊SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
  4. 💊FDA PHARMA TODAY
  5. 💊Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China
  6. 💊FDA PHARMA today
  7. 💊Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries